63.33
-1.31(-2.03%)
Currency In USD
| Previous Close | 64.64 |
| Open | 64.5 |
| Day High | 64.5 |
| Day Low | 61.81 |
| 52-Week High | 70.98 |
| 52-Week Low | 29.31 |
| Volume | 1.71M |
| Average Volume | 1.96M |
| Market Cap | 7.53B |
| PE | -10.05 |
| EPS | -6.3 |
| Moving Average 50 Days | 63.63 |
| Moving Average 200 Days | 46.72 |
| Change | -1.31 |
If you invested $1000 in Cytokinetics, Incorporated (CYTK) 10 years ago, it would be worth $7,204.78 as of January 14, 2026 at a share price of $63.33. Whereas If you bought $1000 worth of Cytokinetics, Incorporated (CYTK) shares 5 years ago, it would be worth $3,198.48 as of January 14, 2026 at a share price of $63.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 9:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare C
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
GlobeNewswire Inc.
Dec 19, 2025 9:00 PM GMT
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Dec 17, 2025 12:30 PM GMT
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,